Insomnia is one of the most common sleep disorders in the United States and other
Western countries, with prevalence estimates ranging between 10% and 15% of the adult
population; up to one third of all adults report insomnia symptoms in a given year
[
[1]
]. The socioeconomic impact of this disease is tremendous. The direct cost of insomnia
(the cost of treatment) has been estimated to be between 10 and 15 billion dollars
per year based on reports published in the early to mid-1990s [
2
,
3
]. That estimate does not include the costs attributable to increased absenteeism and
property damage caused by accidents [
[4]
]. The human cost in terms of medical comorbidities, suffering, and reduced quality
of life is not so easily quantified.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Sleep Medicine ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of insomnia: what we know and what we still need to learn.Sleep Med Rev. 2002; 6: 97-111
- The direct economic costs of insomnia in the United States for 1995.Sleep. 1999; 22: S386-S393
- The socio-economics of insomnia: the materials and the methods.Eur Psychiatry. 1997; 12: 41S-48S
- Professional correlates of insomnia.Sleep. 2006; 29: 171-178
- National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults.Sleep. 2005; 28: 1049-1057
- Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.Sleep. 1991; 14: 399-407
- Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders.J Psychiatr Res. 1997; 31: 333-346
- Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy.JAMA. 1997; 278: 2170-2177
- Meta-analysis of benzodiazepine use in the treatment of insomnia.Can Med Assoc J. 2000; 162: 225-233
- Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia.Clin Neuropharmacol. 2000; 23: 17-21
- Benzodiazepine hypnotics remain effective for 24 weeks.Br Med J (Clin Res Ed). 1982; 284: 860-863
- A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.J Clin Psychiatry. 1994; 55: 192-199
- A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.Sleep Med. 2000; 1: 41-49
- Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.Sleep. 2003; 26: 793-799
- An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.Sleep Med. 2005; 6: 487-495
- Current patterns and future directions in the treatment of insomnia.Ann Clin Psychiatry. 2005; 17: 31-40
- Eight weeks of non-nightly use of zolpidem for primary insomnia.Sleep. 2000; 23: 1087-1096
- Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.J Clin Psychiatry. 2004; 65: 1128-1137
- Are prescribed medications effective in the treatment of insomnia complaints?.J Psychosom Res. 1999; 47: 359-368
- The beneficial and adverse effects of hypnotics.J Clin Psychiatry. 1991; 52: 16-23
- Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.Clin Ther. 2004; 26: 1578-1586
- Zolpidem for persistent insomnia in SSRI-treated depressed patients.J Clin Psychiatry. 1999; 60: 668-676
- Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.Biol Psychiatry. 2006; 59: 1052-1060
- Melatonin in humans.N Engl J Med. 1997; 336: 186-195
- Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.Neuropharmacology. 2005; 48: 301-310
- Melatonin receptors in humans: biological role and clinical relevance.Biomed Pharmacother. 2006; 60: 97-108
- Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.J Clin Psychiatry. 2005; 66: 31-41
- Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.Sleep. 2005; 28: 303-307
- An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia.Sleep Med. 2006; 7: 17-24
Roth T, Seiden D, Weigand S, et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [abstract no. II-87]. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU). Boca Raton (FL), June 6–9, 2005.
- Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia.Sleep. 2005; 28 ([abstract]): A228
- Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.Sleep Med. 2006; 7: 312-318
- Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study.J Psychiatry Neurosci. 2003; 28: 191-196
- Melatonin administration in insomnia.Neuropsychopharmacology. 1990; 3: 19-23
- Melatonin and insomnia.J Sleep Res. 1996; 5: 61-65
- Melatonin treatment for age-related insomnia.J Clin Endocrinol Metab. 2001; 86: 4727-4730
- The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study.Biol Psychiatry. 1991; 30: 371-376
- Melatonin replacement therapy of elderly insomniacs.Sleep. 1995; 18: 598-603
- A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials.Sleep Med. 2003; 4: 57-62
- Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs.Arch Gerontol Geriatr. 1997; 24: 223-231
- Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.Sleep. 2004; 27: 1441-1442
- A review of the evidence for the efficacy and safety of trazodone in insomnia.J Clin Psychiatry. 2005; 66: 469-476
- Trazodone enhances sleep in subjective quality but not in objective duration.Br J Clin Pharmacol. 1983; 16: 139-144
- Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia.Hum Psychopharmacol. 1998; 13: 191-198
- The effects of trazodone on sleep disturbances induced by brofaromine.Eur Psychiatry. 1999; 14: 167-171
- Trazodone for antidepressant-associated insomnia.Am J Psychiatry. 1994; 151: 1069-1072
- [Amitriptyline hydrochloride in the treatment of anxiety and insomnia and as a tranquilizer].Neurol Neurocir Psiquiatr. 1976; 17 ([in Spanish]): 165-169
- [Double-blind comparison between amitriptyline Diffucaps and ordinary amitriptyline in sleep disorders of depressive origin].Acta Psychiatr Belg. 1975; 75 ([in Spanish]): 182-189
- [Amitriptyline in the treatment of anxiety and insomnia anal as a tranquilizer].Neurol Neurocir Psiquiatr. 1976; 17 ([in Spanish]): 133-138
- Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study.Acta Psychiatr Scand. 1998; 97: 233-235
- Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.J Clin Psychiatry. 2001; 62: 453-463
- Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia.Pharmacopsychiatry. 1996; 29: 187-192
- The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.Psychopharmacology (Berl). 2003; 170: 423-428
- The effects of doxepin HCl on sleep and depression.J Clin Psychiatry. 1982; 43: 366-368
- Double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery.Acta Psychiatr Scand. 1985; 71: 339-346
- Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.Biol Psychiatry. 2000; 48: 75-78
- Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens.J Clin Psychopharmacol. 2000; 20: 531-537
- Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.Can J Psychiatry. 2006; 51: 27-34
- Comparative effects of mirtazepine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.J Clin Psychiatry. 2003; 64: 1224-1229
- Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo.Biol Psychiatry. 2000; 47: 468-470
- Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.Biol Psychiatry. 1999; 46: 141-143
- Tiagabine increases slow wave sleep in a dose-dependent fashion, without affecting traditional efficacy measures, in adults with primary insomnia.J Clin Sleep Med. 2006; 2: 35-41
- Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study.Sleep. 2006; 29: 335-341
- Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia.Sleep Med. 2006; 7: 155-161
- Manifestations and management of chronic insomnia in adults. Evidence report/technology assessment no. 125. (University of Alberta Evidence-based Practice Center). Agency for Healthcare Research and Quality Publication # 05–E021–2.Agency for Healthcare Research and Quality, Rockville (MD)2005
Article info
Footnotes
Dr. Feren and Dr. Katyal have served as coinvestigators for research contracts supported by Cephalon, Evotec Neurosciences, Merck & Co., Neurocrine Biosciences, Pfizer, and Somaxon. Dr. Walsh has received research support from Cephalon, Evotec Neurosciences, Merck & Co., Neurocrine Biosciences, Pfizer, and Somaxon and has provided consulting services to Actelion, Cephalon, Elan, Eli Lilly, Evotec Neurosciences, GlaxoSmithKline, Guilford Pfizer, King, Merck & Co., Neurocrine Biosciences, Neurogen, Organon, Respironics, Sepracor, Takeda America, TransOral, Sanofi-Aventis, SleepTech, and Somaxon.
Identification
Copyright
© 2006 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
